Mei Pharma, Common Stock Current Liabilities

LITS Stock   2.09  0.14  7.18%   
Fundamental analysis of MEI Pharma, allows traders to better anticipate movements in MEI Pharma,'s stock price by examining its financial health and performance throughout various phases of its business cycle.
Total Current Liabilities is likely to drop to about 1.3 M in 2025. Non Current Liabilities Total is expected to grow at the current pace this year.
  
Build AI portfolio with MEI Stock
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

MEI Pharma, Common Company Current Liabilities Analysis

MEI Pharma,'s Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.

Current Liabilities

 = 

Payables

+

Accrued Debt

More About Current Liabilities | All Equity Analysis

MEI Current Liabilities Driver Correlations

Understanding the fundamental principles of building solid financial models for MEI Pharma, is extremely important. It helps to project a fair market value of MEI Stock properly, considering its historical fundamentals such as Current Liabilities. Since MEI Pharma,'s main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of MEI Pharma,'s historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of MEI Pharma,'s interrelated accounts and indicators.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
Competition
In accordance with the recently published financial statements, MEI Pharma, Common has a Current Liabilities of 0.0. This indicator is about the same for the average (which is currently at 0.0) sector and about the same as Current Liabilities (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).

MEI Current Liabilities Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses MEI Pharma,'s direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of MEI Pharma, could also be used in its relative valuation, which is a method of valuing MEI Pharma, by comparing valuation metrics of similar companies.
MEI Pharma, is currently under evaluation in current liabilities category among its peers.

MEI Fundamentals

About MEI Pharma, Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze MEI Pharma, Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MEI Pharma, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MEI Pharma, Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for MEI Stock Analysis

When running MEI Pharma,'s price analysis, check to measure MEI Pharma,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MEI Pharma, is operating at the current time. Most of MEI Pharma,'s value examination focuses on studying past and present price action to predict the probability of MEI Pharma,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MEI Pharma,'s price. Additionally, you may evaluate how the addition of MEI Pharma, to your portfolios can decrease your overall portfolio volatility.